Anticoagulant Therapy is a Contentious Issue in COVID-19 Patients
,
Abstract
No AbstractNo AbstractNo AbstractNo AbstractNo AbstractNo Abstract
[1] Mohammadi M, Hadian M R, Varpaei H A. Exercise in COVID-19: Intensity and Timing. Asian J Sports Med.12(3):e113266.
[2] Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine. 2020; 8(6):e46-7.
[3] Pesavento R, Ceccato D, Pasquetto G, Monticelli J, Leone L, Frigo A, et al. The hazard of (sub) therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience. J Thromb Haemost.. 2020; 18(10):2629-35.
[4] Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020. 46(6):1089-1098.
[5] Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Critical Care. 20200; 24(1):275.
[6] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-1099.
[7] Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-7.
[8] Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thromb Haemost. 2020; 18(7):1743-6.
[9] Stessel B, Vanvuchelen C, Bruckers L, Geebelen L, Callebaut I, Vandenbrande J, et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020; 194:209-15.
[10] Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care. 2020; 24(1):364.
[11] Sivaloganathan H, Ladikou EE, Chevassut T. COVID‐19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol. 2020; 190(4):e192-5.
[12] Banik J, Mezera V, Köhler C, Schmidtmann M. Antiplatelet therapy in patients with Covid-19: A retrospective observational study. Thrombosis Update. 2021; 2:100026.
[13] Wang Y, Ao G, Nasr B, Qi X. Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis. Am J Emerg Med. 2021; 43:27-30.
[14] Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995). 2020; 48(4):169-179.
[15] Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, et al. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020; 3(5):e2010478.
[16] Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021; 325(16):1620-1630. https://10.1001/jama.2021.4152
[17] Izadpanah M, Khalili H, Mohammadi M. Comparing safety of heparin as continuous intravenous infusion and multiple subcutaneous injections. J Comp Eff Res. 2016; 5(1):31-8.
[18] El-Ghiaty MA, Shoieb SM, El-Kadi AOS. Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms. Med Hypotheses. 2020; 144:110033.
[19] Schutgens RE. DOAC in COVID-19: Yes or No?. HemaSphere. 2020; 5(1):e526.
[20] Wenzler E, Engineer MH, Yaqoob M, Benken ST. Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease. TH open. 2020; 4(4):e376-e382.
[21] REMAP-CAP, ACTIV-4a, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021; 385(9):777-89.
[22] ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD, Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021; 385(9):790-802.
[23] Voicu S, Chousterman BG, Bonnin P, Deye N, Malissin I, Le Gall A, et al. Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19. J Infect. 2021 May;82(5):186-230.
[24] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed February 24, 2022
[25] Hussain Khan Z, Maki Aldulaimi A, Varpaei H, Mohammadi M. Various Aspects of Non-Invasive Ventilation in COVID-19 Patients: A Narrative Review. Iranian J Med Sci, 2022; 47(3): 194-209.
[26] Hossein Dokht A, Varpaei HA, Mohammadi M, Amiri H. Upper limb deep vein thromboembolism: a case report. Medical Science Journal of Islamic Azad Univesity-Tehran Medical Branch. 2021; 31(4):459-63.
[2] Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. The Lancet Respiratory Medicine. 2020; 8(6):e46-7.
[3] Pesavento R, Ceccato D, Pasquetto G, Monticelli J, Leone L, Frigo A, et al. The hazard of (sub) therapeutic doses of anticoagulants in non‐critically ill patients with Covid‐19: The Padua province experience. J Thromb Haemost.. 2020; 18(10):2629-35.
[4] Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020. 46(6):1089-1098.
[5] Fraissé M, Logre E, Pajot O, Mentec H, Plantefève G, Contou D. Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Critical Care. 20200; 24(1):275.
[6] Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18(5):1094-1099.
[7] Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191:145-7.
[8] Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients. J Thromb Haemost. 2020; 18(7):1743-6.
[9] Stessel B, Vanvuchelen C, Bruckers L, Geebelen L, Callebaut I, Vandenbrande J, et al. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020; 194:209-15.
[10] Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, et al. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care. 2020; 24(1):364.
[11] Sivaloganathan H, Ladikou EE, Chevassut T. COVID‐19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol. 2020; 190(4):e192-5.
[12] Banik J, Mezera V, Köhler C, Schmidtmann M. Antiplatelet therapy in patients with Covid-19: A retrospective observational study. Thrombosis Update. 2021; 2:100026.
[13] Wang Y, Ao G, Nasr B, Qi X. Effect of antiplatelet treatments on patients with COVID-19 infection: A systematic review and meta-analysis. Am J Emerg Med. 2021; 43:27-30.
[14] Watson RA, Johnson DM, Dharia RN, Merli GJ, Doherty JU. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995). 2020; 48(4):169-179.
[15] Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, et al. Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020; 3(5):e2010478.
[16] Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021; 325(16):1620-1630. https://10.1001/jama.2021.4152
[17] Izadpanah M, Khalili H, Mohammadi M. Comparing safety of heparin as continuous intravenous infusion and multiple subcutaneous injections. J Comp Eff Res. 2016; 5(1):31-8.
[18] El-Ghiaty MA, Shoieb SM, El-Kadi AOS. Cytochrome P450-mediated drug interactions in COVID-19 patients: current findings and possible mechanisms. Med Hypotheses. 2020; 144:110033.
[19] Schutgens RE. DOAC in COVID-19: Yes or No?. HemaSphere. 2020; 5(1):e526.
[20] Wenzler E, Engineer MH, Yaqoob M, Benken ST. Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease. TH open. 2020; 4(4):e376-e382.
[21] REMAP-CAP, ACTIV-4a, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021; 385(9):777-89.
[22] ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD, Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021; 385(9):790-802.
[23] Voicu S, Chousterman BG, Bonnin P, Deye N, Malissin I, Le Gall A, et al. Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19. J Infect. 2021 May;82(5):186-230.
[24] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed February 24, 2022
[25] Hussain Khan Z, Maki Aldulaimi A, Varpaei H, Mohammadi M. Various Aspects of Non-Invasive Ventilation in COVID-19 Patients: A Narrative Review. Iranian J Med Sci, 2022; 47(3): 194-209.
[26] Hossein Dokht A, Varpaei HA, Mohammadi M, Amiri H. Upper limb deep vein thromboembolism: a case report. Medical Science Journal of Islamic Azad Univesity-Tehran Medical Branch. 2021; 31(4):459-63.
| Files | ||
| Issue | Vol 8 No 3 (2022): Summer |
|
| Section | Letter to Editor | |
| DOI | https://doi.org/10.18502/aacc.v8i3.9623 | |
| Keywords | ||
| No Keywords | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Varpaei HA, Mohammadi M, Loni S, Hashemi-Amir SY. Anticoagulant Therapy is a Contentious Issue in COVID-19 Patients. Arch Anesth & Crit Care. 2022;8(3):263-266.
